Cargando…

Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibition (ICI) improves survival outcomes for patients with several types of cancer including metastatic melanoma (MM), but serious immune-related adverse events requiring intervention with immunosuppressive medications occur in a subset of patients. Skin toxicity (ST...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gulati, Nicholas, Donnelly, Douglas, Qian, Yingzhi, Moran, Una, Johannet, Paul, Zhong, Judy, Osman, Iman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659132/ https://www.ncbi.nlm.nih.gov/pubmed/33176813 http://dx.doi.org/10.1186/s12967-020-02612-5

Ejemplares similares

Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer
por: Johannet, Paul, et al.
Publicado: (2020)

Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors
por: Gulati, Nicholas, et al.
Publicado: (2021)

Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients
por: Johannet, Paul, et al.
Publicado: (2021)

Clinical outcomes in cancer patients with COVID‐19
por: Sawyers, Amelia, et al.
Publicado: (2021)

Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
por: Johannet, Paul, et al.
Publicado: (2022)

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
por: Gowen, Michael F., et al.
Publicado: (2018)

The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
por: Donnelly, Douglas, et al.
Publicado: (2019)

Optimization of an automated tumor-infiltrating lymphocyte algorithm for improved prognostication in primary melanoma
por: Chou, Margaret, et al.
Publicado: (2020)

The urgency of utilizing COVID-19 biospecimens for research in the heart of the global pandemic
por: Osman, Iman, et al.
Publicado: (2020)

Correction to: The urgency of utilizing COVID-19 biospecimens for research in the heart of the global pandemic
por: Osman, Iman, et al.
Publicado: (2021)

Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma
por: Usyk, Mykhaylo, et al.
Publicado: (2021)

Toxicities associated with checkpoint inhibitors—an overview
por: Spiers, Laura, et al.
Publicado: (2019)

Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors
por: Kamińska-Winciorek, Grażyna, et al.
Publicado: (2019)

How we treat neurological toxicity from immune checkpoint inhibitors
por: Spain, Lavinia, et al.
Publicado: (2019)

Perfect Rainbow Tradeoff with Checkpoints Revisited
por: Hong, Jin
Publicado: (2016)

Immune-checkpoint inhibitors: long-term implications of toxicity
por: Johnson, Douglas B., et al.
Publicado: (2022)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors
por: Jordan, B., et al.
Publicado: (2021)

Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors
por: Al Ashi, Suleiman I, et al.
Publicado: (2021)

Causes of Pruritus in Patients Treated With Immune Checkpoint Inhibitors for Melanomas or Skin Carcinomas
por: Salinas, Nadia, et al.
Publicado: (2021)

Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant
por: Meermeier, Erin W., et al.
Publicado: (2023)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
por: Wong, Selina K., et al.
Publicado: (2021)

Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
por: Joseph, Gwenyth J., et al.
Publicado: (2023)

Skin Biter: Dermatodaxia Revisited
por: Cohen, Philip R
Publicado: (2022)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)

Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors
por: Valachis, Antonios, et al.
Publicado: (2021)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy
por: Nüssing, Simone, et al.
Publicado: (2020)

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
por: Johnson, Douglas B., et al.
Publicado: (2019)

Skin Manifestation Induced by Immune Checkpoint Inhibitors
por: Yamamoto, Toshiyuki
Publicado: (2022)

Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review
por: Sławiński, Grzegorz, et al.
Publicado: (2020)

Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
por: Nuzzo, Pier Vitale, et al.
Publicado: (2020)

Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
por: Genta, Sofia, et al.
Publicado: (2023)

Glutathione revisited: a better scavenger than previously thought
por: Haenen, Guido R. M. M., et al.
Publicado: (2014)

Access to Employment as Access to Health:: Revisiting the Better Bottom Line
por: Roberts, Jody A.
Publicado: (2021)

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
por: Qian, Xinye, et al.
Publicado: (2022)

Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis
por: Sun, Qian, et al.
Publicado: (2022)

Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades
por: Wang, Xiaoyan, et al.
Publicado: (2021)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rn4q25s0gu92bvno577ng3i7f0